Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed syrian hamsters

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 12, 2014, Pages 7171-7181

  Ying, Baoling ^a   Tollefson, Ann E ^a   Spencer, Jacqueline F ^a   Balakrishnan, Lata ^b   Dewhurst, Stephen ^b   Capella, Cristina ^a   Buller, R Mark L ^c   Toth, Karoly ^a   Wold, William S M ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; GANCICLOVIR; VIRUS DNA; VIRUS ENZYME; AMINOTRANSFERASE; ANTIVIRUS AGENT; BRINCIDOFOVIR; CYTOSINE; DNA DIRECTED DNA POLYMERASE; PHOSPHONIC ACID DERIVATIVE; VIRUS PROTEIN;

ADENOVIRUS INFECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA REPLICATION; DNA SYNTHESIS; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HAMSTER MODEL; HUMAN; HUMAN ADENOVIRUS 5; HUMAN CELL; IMMUNOCOMPROMISED PATIENT; LIVER; MALE; MORBIDITY; MORTALITY; NONHUMAN; SINGLE DRUG DOSE; SURVIVAL; SYRIAN HAMSTER; VIRUS GENOME; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS VIRULENCE; ADENOVIRIDAE INFECTIONS; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; BODY WEIGHT; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN ADENOVIRUS C; IMMUNOCOMPROMIZED PATIENT; IMMUNOLOGY; MESOCRICETUS; METABOLISM; PATHOGENICITY; TUMOR CELL LINE; VIROLOGY;

ADENOVIRIDAE INFECTIONS; ADENOVIRUSES, HUMAN; ANIMALS; ANTIVIRAL AGENTS; BODY WEIGHT; CELL LINE, TUMOR; CYTOSINE; DNA-DIRECTED DNA POLYMERASE; FEMALE; GANCICLOVIR; GENE EXPRESSION; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MESOCRICETUS; ORGANOPHOSPHONATES; SURVIVAL ANALYSIS; TRANSAMINASES; VIRAL LOAD; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84912099589     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03860-14     Document Type: Article

References (55)

1. th ed (electronic). Lippincott Williams & Wilkins, Philadelphia, PA.
2. Russell WC. 2009. Adenoviruses: update on structure and function. J. Gen. Virol. 90:1-20. http://dx.doi.org/10.1099/vir.0.003087-0.
3. th ed (electronic). Lippincott Williams & Wilkins, Philadelphia, PA.
4. Collins RH, Jr, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, Horowitz M, Parker P. 2000. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant. 26:511-516. http://dx.doi.org/10.1038/sj.bmt.1702555.
5. Ison MG. 2006. Adenovirus infections in transplant recipients. Clin. Infect. Dis. 43:331-339. http://dx.doi.org/10.1086/505498.
6. Echavarria M. 2008. Adenoviruses in immunocompromised hosts. Clin. Microbiol. Rev. 21:704-715. http://dx.doi.org/10.1128/CMR.00052-07.
7. Lindemans CA, Leen AM, Boelens JJ. 2010. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 116:5476-5485. http: //dx.doi.org/10.1182/blood-2010-04-259291.
8. Lenaerts L, De Clercq E, Naesens L. 2008. Clinical features and treatment of adenovirus infections. Rev. Med. Virol. 18:357-374. http://dx.doi.org /10.1002/rmv.589.
9. Matthes-Martin S, Boztug H, Lion T. 2013. Diagnosis and treatment of adenovirus infection in immunocompromised patients. Expert Rev. Anti Infect. Ther. 11:1017-1028. http://dx.doi.org/10.1586/14787210.2013.836964.
10. Stercz B, Nagy K, Ongradi J. 2012. Adenovirus infections in immunocompromised patients. Orv. Hetil. 153:1896-1904. (In Hungarian.) http: //dx.doi.org/10.1556/OH.2012.29496.
11. Florescu DF, Pergam SA, Neely MN, Qiu F, Johnston C, Way S, Sande J, Lewinsohn DA, Guzman-Cottrill JA, Graham ML, Papanicolaou G, Kurtzberg J, Rigdon J, Painter W, Mommeja-Marin H, Lanier R, Anderson M, van der Horst C. 2012. Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. Biol. Blood Marrow Transplant. 18:731-738. http://dx.doi.org /10.1016/j.bbmt.2011.09.007.
12. Lenaerts L, Naesens L. 2006. Antiviral therapy for adenovirus infections. Antiviral Res. 71:172-180. http://dx.doi.org/10.1016/j.antiviral.2006.04.007.
13. Wold WS, Toth K. 2012. Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds. Adv. Cancer Res. 115:69-92. http://dx.doi.org/10.1016/B978-0 -12-398342-8.00003-3.
14. Toth K, Spencer JF, Dhar D, Sagartz JE, Buller RM, Painter GR, Wold WSM. 2008. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovi-rus-induced mortality in a permissive, immunosuppressed animal model. Proc. Natl. Acad. Sci. U. S. A. 105:7293-7297. http://dx.doi.org/10.1073 /pnas.0800200105.
15. Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, Wold WS. 2006. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res. 66:1270-1276. http://dx.doi.org/10.1158/0008-5472.CAN-05-3497.
16. Dhar D, Spencer JF, Toth K, Wold WSM. 2009. Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model. Mol. Ther. 17: 1724-1732. http://dx.doi.org/10.1038/mt.2009.156.
17. Lichtenstein DL, Spencer JF, Doronin K, Patra D, Meyer J, Shashkova EV, Kuppuswamy M, Dhar D, Thomas MA, Tollefson AE, Zumstein LA, Wold WSM, Toth K. 2009. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wild-type Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther. 16:644-654. http://dx.doi.org/10.1038 /cgt.2009.5.
18. Ying B, Toth K, Spencer JF, Meyer J, Tollefson AE, Patra D, Dhar D, Shashkova EV, Kuppuswamy M, Doronin K, Thomas MA, Zumstein LA, Wold WSM, Lichtenstein DL. 2009. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther. 16:625-637. http://dx.doi.org /10.1038/cgt.2009.6.
19. Evans CM, Kudesia G, McKendrick M. 2013. Management of herpesvirus infections. Int. J. Antimicrob. Agents 42:119-128. http://dx.doi.org /10.1016/j.ijantimicag.2013.04.023.
20. Matthews T, Boehme R. 1988. Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10:S490-S494. http://dx.doi.org/10.1093 /clinids/10.Supplement-3.S490.
21. th ed, vol 1 (electronic). Lippincott Williams & Wilkins, Philadelphia, PA.
22. Naesens L, Lenaerts L, Andrei G, Snoeck R, Van Beers D, Holy A, Balzarini J, De Clercq E. 2005. Antiadenovirus activities of several classes of nucleoside and nucleotide analogues. Antimicrob. Agents Chemother. 49:1010-1016. http://dx.doi.org/10.1128/AAC.49.3.1010-1016.2005.
23. Trousdale MD, Goldschmidt PL, Nobrega R. 1994. Activity of ganciclovir against human adenovirus type-5 infection in cell culture and cotton rat eyes. Cornea 13:435-439. http://dx.doi.org/10.1097/00003226-199409000-00011.
24. Kodama E, Shigeta S, Suzuki T, De Clercq E. 1996. Application of a gastric cancer cell line (MKN-28) for anti-adenovirus screening using the MTT method. Antiviral Res. 31:159-164. http://dx.doi.org/10.1016/0166 -3542(96)06966-5.
25. Antimicrob. Agents Chemother. 22:55-61. http://dx.doi.org/10.1128 /AAC.22.1.55.
26. Wreghitt TG, Gray JJ, Ward KN, Salt A, Taylor DL, Alp NJ, Tyms AS. 1989. Disseminated adenovirus infection after liver transplantation and its possible treatment with ganciclovir. J. Infect. 19:88-89. http://dx.doi.org /10.1016/S0163-4453(89)95214-6.
27. Tabbara KF, Omar N, Hammouda E, Akanuma M, Ohguchi T, Ariga T, Tagawa Y, Kitaichi N, Ishida S, Aoki K, Ishiko H, Ohno S. 2010. Molecular epidemiology of adenoviral keratoconjunctivitis in Saudi Arabia. Mol. Vis. 16:2132-2136.
28. Gordon YJ, Romanowski E, Araullo-Cruz T, Seaberg L, Erzurum S, Tolman R, De Clercq E. 1991. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2=-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res. 16:11-16. http://dx.doi.org/10 .1016/0166-3542(91)90054-U.
29. Taylor DL, Jeffries DJ, Taylor-Robinson D, Parkin JM, Tyms AS. 1988. The susceptibility of adenovirus infection to the anti-cytomegalovirus drug, ganciclovir (CHPG). FEMS Microbiol. Lett. 49:337-341. http://dx .doi.org/10.1111/j.1574-6968.1988.tb02753.x.
30. Avivi I, Chakrabarti S, Milligan DW, Waldmann H, Hale G, Osman H, Ward KN, Fegan CD, Yong K, Goldstone AH, Linch DC, Mackinnon S. 2004. Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. Biol. Blood Marrow Transplant. 10:186-194. http://dx.doi.org/10.1016/j.bbmt.2003 .11.001.
31. Bruno B, Gooley T, Hackman RC, Davis C, Corey L, Boeckh M. 2003. Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. Biol. Blood Marrow Transplant. 9:341-352. http://dx.doi.org/10.1016/S1083-8791(03)00102-2.
32. Lenaerts L, Kelchtermans H, Geboes L, Matthys P, Verbeken E, De Clercq E, Naesens L. 2008. Recovery of humoral immunity is critical for successful antiviral therapy in disseminated mouse adenovirus type 1 infection. Antimicrob. Agents Chemother. 52:1462-1471. http://dx.doi.org /10.1128/AAC.01311-07.
33. Chen FE, Liang RH, Lo JY, Yuen KY, Chan TK, Peiris M. 1997. Treatment of adenovirus-associated haemorrhagic cystitis with ganciclovir. Bone Marrow Transplant. 20:997-999. http://dx.doi.org/10.1038/sj .bmt.1700997.
34. Blohme I, Nyberg G, Jeansson S, Svalander C. 1992. Adenovirus infection in a renal transplant patient. Transplant. Proc. 24:295.
35. Duggan JM, Farrehi J, Duderstadt S, Turner NJ, Fekety R. 1997. Treatment with ganciclovir of adenovirus pneumonia in a cardiac transplant patient. Am. J. Med. 103: 439-440. http://dx.doi.org/10 .1016/S0002-9343(97)85997-9.
36. Shashkova EV, Spencer JF, Wold WSM, Doronin K. 2007. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus. Mol. Ther. 15: 598-607. http://dx.doi.org/10.1038/sj.mt.6300064.
37. nd ed, vol 1. Humana Press, Totowa, NJ.
38. Lillie JW, Loewenstein PM, Green MR, Green M. 1987. Functional domains of adenovirus type 5 E1a proteins. Cell 50:1091-1100. http://dx .doi.org/10.1016/0092-8674(87)90175-9.
39. Cepko CL, Whetstone CA, Sharp PA. 1983. Adenovirus hexon monoclonal antibody that is group specific and potentially useful as a diagnostic reagent. J. Clin. Microbiol. 17:360-364.
40. Cauthen AN, Welton AR, Spindler KR. 2007. Construction of mouse adenovirus type 1 mutants. Methods Mol. Med. 130:41-59. http://dx.doi .org/10.1385/1-59745-166-5:41.
41. Capella C, Beltejar MJ, Brown C, Fong V, Daddacha W, Kim B, Dewhurst S. 2012. Selective modification of adenovirus replication can be achieved through rational mutagenesis of the adenovirus type 5 DNA polymerase. J. Virol. 86:10484-10493. http://dx.doi.org/10.1128/JVI.00739-12.
42. Pike JE, Henry RA, Burgers PM, Campbell JL, Bambara RA. 2010. An alternative pathway for Okazaki fragment processing: resolution of foldback flaps by Pif1 helicase. J. Biol. Chem. 285:41712-41723. http://dx.doi .org/10.1074/jbc.M110.146894.
43. Thomas GP, Mathews MB. 1980. DNA replication and the early to late transition in adenovirus infection. Cell 22:523-533. http://dx.doi.org/10 .1016/0092-8674(80)90362-1.
44. Sugawara K, Gilead Z, Wold WSM, Green M. 1977. Immunofluores-Downloaded from http://aac.asm.org/ on November 25, 2014 by Elsevier Bibliographic Databases cence study of the adenovirus type 2 single-strandedDNAbinding protein in infected and transformed cells. J. Virol. 22:527-539.
45. Voelkerding K, Klessig DF. 1986. Identification of two nuclear subclasses of the adenovirus type 5-encoded DNA-binding protein. J. Virol. 60: 353-362.
46. Kaufman HE. 2011. Adenovirus advances: new diagnostic and therapeutic options. Curr. Opin. Ophthalmol. 22:290-293. http://dx.doi.org/10 .1097/ICU.0b013e3283477cb5.
47. Colin J. 2007. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin. Ophthalmol. 1:441-453.
48. Meyer-Rusenberg B, Loderstadt U, Richard G, Kaulfers PM, Gesser C. 2011. Epidemic keratoconjunctivitis: the current situation and recommendations for prevention and treatment. Dtsch. Arztebl. Int. 108:475-480. http://dx.doi.org/10.3238/arztebl.2011.0475.
49. Yabiku ST, Yabiku MM, Bottos KM, Araujo AL, Freitas D, Belfort R, Jr. 2011. Ganciclovir 0.15% ophthalmic gel in the treatment of adenovirus keratoconjunctivitis. Arq. Bras. Oftalmol. 74:417-421. (In Portuguese.) http://dx.doi.org/10.1590/S0004-27492011000600007.
50. Center for Drug Evaluation and Research. 2005, posting date. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Center for Drug Evaluation and Research Food and Drug Administration, Rockville, MD.
51. Holland GN, Sidikaro Y, Kreiger AE, Hardy D, Sakamoto MJ, Frenkel LM, Winston DJ, Gottlieb MS, Bryson YJ, Champlin RE, Ho WG, Winters RE, Wolfe PR, Cherry JD. 1987. Treatment of cytomegalovirus retinopathy with ganciclovir. Ophthalmology 94:815-823. http://dx.doi .org/10.1016/S0161-6420(87)33534-1.
52. Kit S, Nakajima K, Dubbs DR. 1970. Origin of thymidine kinase in adenovirus-infected human cell lines. J. Virol. 5:446-450.
53. Cheetham BF, Shaw DC, Bellett AJ. 1982. Adenovirus type 5 induces progression of quiescent rat cells into S phase without polyamine accumulation. Mol. Cell. Biol. 2:1295-1298.
54. Wildner O, Hoffmann D, Jogler C, Uberla K. 2003. Comparison of HSV-1 thymidine kinase-dependent and -independent inhibition of rep-lication-competent adenoviral vectors by a panel of drugs. Cancer Gene Ther. 10:791-802. http://dx.doi.org/10.1038/sj.cgt.7700638.
55. Ibrisimovic M, Nagl U, Kneidinger D, Rauch M, Lion T, Klein R. 2012. Targeted expression of herpes simplex virus thymidine kinase in adenovi-rus-infected cells reduces virus titers upon treatment with ganciclovir in vitro. J. Gene Med. 14:3-19. http://dx.doi.org/10.1002/jgm.1638.